Stryker Corporation

Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.

Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

Integer Holdings Corporation provides custom battery packs to energy, military, and environmental markets for use in extreme environments.

Abbott Laboratories (ABT) reported sales of $7.6 billion and adjusted diluted EPS (earnings per share) of $0.74 for fiscal 4Q17.

On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017.

Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]

On November 9, 2017, Stryker (SYK) announced FDA approval for the Neuroform Atlas Stent System, which is approved for marketing under an HDE.

Zimmer Biomet Holdings witnessed a strong performance in its Asia-Pacific region. It contributed 16% to the company’s total sales.

Mako sales in 3Q17 In 3Q17, Stryker sold 33 Mako robots, compared with 30 robots in 3Q16. In 2Q17, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application […]

Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.

Johnson & Johnson’s (JNJ) medical device business has been restructuring in order to focus on higher growth areas with potential expansion opportunities.

Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.

On May 1, 2017, Medtronic announced the FDA approval of its Resolute Onyx DES (drug eluting stent) for adult patients suffering from coronary artery disease.

In fiscal 1Q18, Medtronic (MDT) reported ~26.9% of operating margin on a constant currency basis. This represented year-over-year growth of ~50 basis points.

Medtronic (MDT) registered revenues of ~$1.0 billion revenues from emerging markets in fiscal 1Q18, which represents YoY (year-over-year) sales growth of ~11% in that market.

On August 23, Stryker (SYK) announced a voluntary product recall of specific lots of oral care products that form part of the company’s Sage business unit.

Medtronic’s (MDT) Hospital Solutions segment registered double-digit growth in fiscal 1Q18.

Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.

About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.

On March 23, 2015, the FDA approved Abiomed’s Impella 2.5 heart pump as a temporary ventricular support device.

To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.

In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule.

Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16.

Most of Stryker’s emerging market sales are from China. However, Europe and emerging markets sales have witnessed high growth in recent quarters.

Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections.

On June 6, 2017, Medtronic (MDT) received the Health Canada license for its SureTune3 software for DBS (deep brain stimulation) therapy.

Zimmer Biomet Holdings (ZBH) was trading at $118.40 on May 30, 2017. It has a 50-day moving average of $119.70 and a 200-day moving average of $114.20.

In February 2016, Zimmer Biomet authorized up to $1.0 billion of the company’s common stock for share repurchases, all of which remains authorized to date.

On January 3, DePuy Synthes, a subsidiary of Johnson & Johnson (JNJ), entered into an asset purchase and development agreement with Interventional Spine.

On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.

Thermo Fisher Scientific (TMO) completed the acquisition of FEI Company on September 19, 2016.

Of Medtronic’s ~$7.3 billion in worldwide revenue in fiscal 2Q17, ~$1.8 billion came from its RTG segment, representing ~25% of the company total.

Cost transformation growth is one of Stryker’s key strategies for driving growth. The company has come a long way from its decentralized structure prior to 2010.

On September 27, 2016, Boston Scientific (BSX) announced the acquisition of EndoChoice Holdings for $210 million.

Europe represents a potential growth opportunity for Stryker, as the company currently has a low market share in Europe compared to other developed markets.

After the release of its 2Q16 earnings results on July 28, 2016, Zimmer Biomet Holdings (ZBH) was trading at a forward price-to-earnings multiple in the range of 15.5x–16.2x.

Thermo Fisher has a presence in more than 50 countries. It generates ~19% of its revenues from emerging markets and the rest from developed markets.

C. R. Bard’s (BCR) Oncology segment contributes around 27% of the total revenues of the company.

Intuitive Surgical (ISRG) defines its business model as a “razor/razor blade” model. What does this mean?

Intuitive Surgical follows a diversified sales strategy and doesn’t generate more than 10% of its revenue through any one customer.

Zimmer Biomet (ZBH) is one of the leading hip implant providers in the United States, with approximately 31% market share.

Zimmer Biomet (ZBH) is the leading provider of knee implants in the United States. It has approximately 40% market share, followed by Stryker, Johnson & Johnson, and Smith & Nephew.

Zimmer Biomet has spent $125 million in share repurchases so far in 2016. In February, it authorized up to $1 billion of the company’s common stock for share repurchases.

On January 26, Medtronic completed the acquisition of Covidien for $42.9 billion in cash and Medtronic stocks and assumed Covidien’s debt of ~$5 billion.

Johnson and Johnson’s (JNJ) medical device business segment comprises of cardiovascular, diabetes care, orthopedics, surgery, and vision care divisions.

Between 2012 and 2014, Stryker (SYK) entered into a number of mergers and acquisition deals, investing ~$3.4 billion.

Stryker has expanded its portfolio and geographic reach through mergers and acquisitions and product development. It saw a 7.3% sales growth in 2014.

Stryker’s MedSurg segment reported an increase of 10.8% in net sales in 2014, driven by increased demand in instruments, medical products, and acquisitions.